Gender and Antidepressants

Robert Bies, Kristin L. Bigos, Bruce G. Pollock

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

This chapter discusses the role of gender in administration of antidepressant drugs. There are marked gender differences in the epidemiology of depression, however antidepressants, like most other medications, are developed regardless ofthe sex of the patient. The prior exclusion of women of childbearing age from pharmacokinetic (PK) studies is especially pertinent for antidepressants because of the marked gender differences in the epidemiology of depression. From puberty until menopause, nearly twice as many women (12%) as men (7%) are affected by a depressive disorder each year. Women also exhibit more atypical symptoms of depression, with greater somatization, increased suicide attempts, and comorbid anxiety, whereas men tend to have more comorbid alcohol or drug abuse and completed suicides. Although the evidence is limited, gender-related differences in pharmacodynamics and PK have been shown for several agents. Medications could also have effects on the metabolizing pathways for various hormones. The resulting changes in hormone concentrations could contribute to attenuated responses or the occurrence of an adverse event or have a protective effect. An additional underexplored topic is whether exogenous hormone therapy (i.e., oral contraceptives and hormone replacement therapy) may be affected by antidepressants or vice versa.

Original languageEnglish (US)
Title of host publicationPrinciples of Gender-Specific Medicine
PublisherElsevier Inc.
Pages860-868
Number of pages9
Volume2
ISBN (Print)9780124409057
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Antidepressive Agents
Hormones
Epidemiology
Pharmacokinetics
Depression
Suicide
Pharmacodynamics
Hormone Replacement Therapy
Puberty
Depressive Disorder
Oral Contraceptives
Menopause
Alcoholism
Substance-Related Disorders
Anxiety
Alcohols
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bies, R., Bigos, K. L., & Pollock, B. G. (2004). Gender and Antidepressants. In Principles of Gender-Specific Medicine (Vol. 2, pp. 860-868). Elsevier Inc.. https://doi.org/10.1016/B978-012440905-7/50350-9

Gender and Antidepressants. / Bies, Robert; Bigos, Kristin L.; Pollock, Bruce G.

Principles of Gender-Specific Medicine. Vol. 2 Elsevier Inc., 2004. p. 860-868.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bies, R, Bigos, KL & Pollock, BG 2004, Gender and Antidepressants. in Principles of Gender-Specific Medicine. vol. 2, Elsevier Inc., pp. 860-868. https://doi.org/10.1016/B978-012440905-7/50350-9
Bies R, Bigos KL, Pollock BG. Gender and Antidepressants. In Principles of Gender-Specific Medicine. Vol. 2. Elsevier Inc. 2004. p. 860-868 https://doi.org/10.1016/B978-012440905-7/50350-9
Bies, Robert ; Bigos, Kristin L. ; Pollock, Bruce G. / Gender and Antidepressants. Principles of Gender-Specific Medicine. Vol. 2 Elsevier Inc., 2004. pp. 860-868
@inbook{8da5ef298ff24cd389c42baf95c8180f,
title = "Gender and Antidepressants",
abstract = "This chapter discusses the role of gender in administration of antidepressant drugs. There are marked gender differences in the epidemiology of depression, however antidepressants, like most other medications, are developed regardless ofthe sex of the patient. The prior exclusion of women of childbearing age from pharmacokinetic (PK) studies is especially pertinent for antidepressants because of the marked gender differences in the epidemiology of depression. From puberty until menopause, nearly twice as many women (12{\%}) as men (7{\%}) are affected by a depressive disorder each year. Women also exhibit more atypical symptoms of depression, with greater somatization, increased suicide attempts, and comorbid anxiety, whereas men tend to have more comorbid alcohol or drug abuse and completed suicides. Although the evidence is limited, gender-related differences in pharmacodynamics and PK have been shown for several agents. Medications could also have effects on the metabolizing pathways for various hormones. The resulting changes in hormone concentrations could contribute to attenuated responses or the occurrence of an adverse event or have a protective effect. An additional underexplored topic is whether exogenous hormone therapy (i.e., oral contraceptives and hormone replacement therapy) may be affected by antidepressants or vice versa.",
author = "Robert Bies and Bigos, {Kristin L.} and Pollock, {Bruce G.}",
year = "2004",
doi = "10.1016/B978-012440905-7/50350-9",
language = "English (US)",
isbn = "9780124409057",
volume = "2",
pages = "860--868",
booktitle = "Principles of Gender-Specific Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Gender and Antidepressants

AU - Bies, Robert

AU - Bigos, Kristin L.

AU - Pollock, Bruce G.

PY - 2004

Y1 - 2004

N2 - This chapter discusses the role of gender in administration of antidepressant drugs. There are marked gender differences in the epidemiology of depression, however antidepressants, like most other medications, are developed regardless ofthe sex of the patient. The prior exclusion of women of childbearing age from pharmacokinetic (PK) studies is especially pertinent for antidepressants because of the marked gender differences in the epidemiology of depression. From puberty until menopause, nearly twice as many women (12%) as men (7%) are affected by a depressive disorder each year. Women also exhibit more atypical symptoms of depression, with greater somatization, increased suicide attempts, and comorbid anxiety, whereas men tend to have more comorbid alcohol or drug abuse and completed suicides. Although the evidence is limited, gender-related differences in pharmacodynamics and PK have been shown for several agents. Medications could also have effects on the metabolizing pathways for various hormones. The resulting changes in hormone concentrations could contribute to attenuated responses or the occurrence of an adverse event or have a protective effect. An additional underexplored topic is whether exogenous hormone therapy (i.e., oral contraceptives and hormone replacement therapy) may be affected by antidepressants or vice versa.

AB - This chapter discusses the role of gender in administration of antidepressant drugs. There are marked gender differences in the epidemiology of depression, however antidepressants, like most other medications, are developed regardless ofthe sex of the patient. The prior exclusion of women of childbearing age from pharmacokinetic (PK) studies is especially pertinent for antidepressants because of the marked gender differences in the epidemiology of depression. From puberty until menopause, nearly twice as many women (12%) as men (7%) are affected by a depressive disorder each year. Women also exhibit more atypical symptoms of depression, with greater somatization, increased suicide attempts, and comorbid anxiety, whereas men tend to have more comorbid alcohol or drug abuse and completed suicides. Although the evidence is limited, gender-related differences in pharmacodynamics and PK have been shown for several agents. Medications could also have effects on the metabolizing pathways for various hormones. The resulting changes in hormone concentrations could contribute to attenuated responses or the occurrence of an adverse event or have a protective effect. An additional underexplored topic is whether exogenous hormone therapy (i.e., oral contraceptives and hormone replacement therapy) may be affected by antidepressants or vice versa.

UR - http://www.scopus.com/inward/record.url?scp=38349134490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349134490&partnerID=8YFLogxK

U2 - 10.1016/B978-012440905-7/50350-9

DO - 10.1016/B978-012440905-7/50350-9

M3 - Chapter

SN - 9780124409057

VL - 2

SP - 860

EP - 868

BT - Principles of Gender-Specific Medicine

PB - Elsevier Inc.

ER -